外泌体lncRNA OGFRP1在84例非小细胞肺癌中的表达及临床意义

doi:10.6040/j.issn.1671-7554.0.2020.1127

摘要/Abstract

摘要： 目的探讨长链非编码 RNA(lncRNA)OGFRP1 在非小细胞肺癌(NSCLC)血清外泌体中的表达及临床意义。方法分别对84例初诊为NSCLC的患者及84例正常健康者的血清进行外泌体提取鉴定、RNA提取及检测lncRNA表达。统计学分析血清外泌体lncRNA OGFRP1诊断NSCLC的灵敏度、特异度与准确性,分析 lncRNA OGFRP1 的表达与临床病理特征的关系。结果 84例初诊为NSCLC的患者均经病理学证实为NSCLC。lncRNA OGFRP1 在NSCLC血清外泌体中显著高表达(χ2=96.459,P<0.001)。以病理诊断为金标准,lncRNA OGFRP1测值对NSCLC的辅助诊断的灵敏度、特异度和准确性分别为90.5%、86.9%和93.9%,高于癌胚抗原,差异有统计学意义(P<0.001)。血清外泌体lncRNA OGFRP1的相对表达量与NSCLC癌患者的淋巴结转移(P=0.034)以及T分期(P=0.030)差异有统计学意义。结论血清外泌体lncRNA OGFRP1 的检测对于诊断NSCLC具有较高的灵敏度、特异度和准确性,可作为NSCLC早期筛选、检测和分期的新型肿瘤标志物。

关键词: 非小细胞肺癌, 长链非编码RNA OGFRP1, 外泌体, 癌胚抗原

Abstract: Objective To explore the expression and clinical significance of long non-coding RNA(lncRNA)OGFRP1 in serum exosomes of non-small cell lung cancer(NSCLC). Methods A total of 84 cases preliminarily diagnosed as NSCLC and 84 healthy controls were enrolled. The serum exosomes were extracted and identified, the RNA was extracted, and lncRNA expression was detected. The sensitivity, specificity and diagnostic accuracy of lncRNA OGFRP1 were statistically analyzed. The relationship between the lncRNA OGFRP1 expression and clinicopathological factors were analyzed. Results All cases were pathologically confirmed as NSCLC. lncRNA OGFRP1 was highly expressed in NSCLC(χ2=96.459, P<0.001). With pathological diagnosis as the gold standard, the sensitivity, specificity and accuracy of lncRNA OGFRP1 in the auxiliary diagnosis of NSCLC were 89.4%, 87.9% and 89.4%, respectively, higher than those of carcino-embryonic antigen(P<0.01). The relative expression of lncRNA OGFRP1 in serum exosomes was significantly associated with lymph node metastasis(P=0.034)and T stage(P=0.030)in NSCLC patients. Conclusion The detection of exosomal lncRNA OGFRP1 has high sensitivity, specificity and accuracy in the diagnosis of NSCLC, which can be used as a novel tumor marker for early screening, diagnosis and staging of NSCLC.

Key words: Non-small cell lung cancer, Long non-coding RNA OGFRP1, Exosome, Carcino-embryonic Antigen

中图分类号:

R734.2

刘小璟,夏西燕,肖珂,陈文丹,庄学伟. 外泌体lncRNA OGFRP1在84例非小细胞肺癌中的表达及临床意义[J]. 山东大学学报 (医学版), 2020, 58(11): 71-75.

LIU Xiaojing, XIA Xiyan, XIAO Ke, CHEN Wendan, ZHUANG Xuewei. Expression and clinical significance of exosomal long non-coding RNA OGFRP1 in 84 cases of non-small cell lung cancer[J]. Journal of Shandong University (Health Sciences), 2020, 58(11): 71-75.

参考文献

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019 [J]. CA Cancer J Clin, 2019, 69(1): 7-34.
[2] Anglim PP, Alonzo TA, Laird-Offringa IA. DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update [J]. Mol Cancer, 2008, 7: 81. doi: 10.1186/1476-4598-7-81.
[3] Boolell V, Alamgeer M, Watkins DN, et al. The evolution of therapies in non-small cell lung cancer [J]. Cancers(Basel), 2015,7(3):1815-1846.
[4] Brainard J, Farver C. The diagnosis of non-small cell lung cancer in the molecular era [J]. Mod Pathol, 2019, 32(Suppl 1): 16-26.
[5] Kadara H, Scheet P, Wistuba II, et al. Early events in the molecular pathogenesis of lung cancer [J]. Cancer Prev Res(Phila), 2016, 9(7): 518-527.
[6] Derrien T, Johnson R, Bussotti G, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression [J]. Genome Res, 2012, 22(9): 1775-1789.
[7] Harrow J, Frankish A, Gonzalez JM, et al. GENCODE: the reference human genome annotation for the ENCODE Project [J]. Genome Res, 2012, 22(9): 1760-1774.
[8] Chen R, Xu X, Qian Z, et al. The biological functions and clinical applications of exosomes in lung cancer [J]. Cell Mol Life Sci, 2019, 76(23): 4613-4633.
[9] Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses [J]. Nucleic Acids Res, 2017, 45(W1): W98-W102.
[10] Fong KM, Minna JD. Molecular biology of lung cancer: clinical implications [J]. Clin Chest Med, 2002, 23(1): 83-101.
[11] Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions [J]. Oncologist, 2008(Suppl 1): 5-13. doi: 10.1634/theoncologist.13-S1-5.
[12] Kalluri R. The biology and function of exosomes in cancer [J]. J Clin Invest, 2016, 126(4): 1208-1215.
[13] Ludwig AK, Giebel B. Exosomes: small vesicles participating in intercellular communication [J]. Int J Biochem Cell Biol, 2012, 44(1): 11-15.
[14] Gross JC, Chaudhary V, Bartscherer K, et al. Active wnt proteins are secreted on exosomes [J]. Nat Cell Biol, 2012, 14(10): 1036-1045.
[15] Boelens MC, Wu TJ, Nabet BY, et al. Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways [J]. Cell, 2014, 159(3): 499-513.
[16] Hassanpour M, Rezabakhsh A, Rezaie J, er al. Exosomal cargos modulate autophagy in recipient cells via different signaling pathways [J]. Cell Biosci, 2020, 10: 92. doi: 10.1186/s13578-020-00455-7.
[17] Ransohoff JD, Wei Y, Khavari PA. The functions and unique features of long intergenic non-coding RNA [J]. Nat Rev Mol Cell Biol, 2018, 19(3): 143-157.
[18] Cabili MN, Trapnell C, Goff L, et al. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses [J]. Genes Dev, 2011, 25(18): 1915-1927.
[19] Gloss BS, Dinger ME. The specificity of long noncoding RNA expression[J]. Biochim Biophys Acta, 2016, 1859(1): 16-22.
[20] Arcaro A. Targeting PI3K/mTOR signaling in cancer [J]. Front Oncol, 2014, 4: 84. doi: 10.3389/fonc.2014.00084.
[21] Tang XD, Zhang DD, Jia L, et al. lncRNA AFAP1-AS1 promotes migration and invasion of non-small cell lung cancer via up-regulating IRF7 and the RIG-I-Like receptor signaling pathway [J]. Cell Physiol Biochem, 2018, 50(1): 179-195.
[22] Cui Y, Zhang F, Zhu C, et al. Upregulated lncRNA SNHG1 contributes to progression of non-small cell lung cancer through inhibition of miR-101-3p and activation of Wnt/β-catenin signaling pathway [J]. Oncotarget, 2017, 8(11): 17785-17794.
[23] Weber DG, Johnen G, Casjens S, et al. Evaluation of long noncoding RNA MALAT1 as a candidate blood-based biomarker for the diagnosis of non-small cell lung cancer [J]. BMC Res Notes, 2013, 6: 518. doi: 10.1186/1756-0500-6-518.
[24] Yu H, Xu Q, Liu F, et al. Identification and validation of long noncoding RNA biomarkers in human non-small-cell lung carcinomas [J]. J Thorac Oncol, 2015, 10(4): 645-654.
[25] Wang P, Lu S, Mao H, et al. Identification of biomarkers for the detection of early stage lung adenocarcinoma by microarray profiling of long noncoding RNAs [J]. Lung Cancer, 2015, 88(2): 147-153.

相关文章 15

[1]	黄佩文, 王旭东. 治疗非小细胞肺癌新药:靶向c-Met蛋白的抗体药物偶联物Telisotuzumab Vedotin[J]. 山东大学学报 (医学版), 2026, 64(3): 124-130.
[2]	赵汉卿,周新睿,李子建,唐兴. 循环肿瘤细胞联合血清学检测在非小细胞肺癌中的应用[J]. 山东大学学报 (医学版), 2025, 63(5): 79-85.
[3]	徐年兴,魏东,乔俊杰,战炳炎. CD8⁺、IL-6和PaO₂对不可切除Ⅲ_B/C和Ⅳ期非小细胞肺癌免疫治疗触发放射召回性肺炎的预测价值[J]. 山东大学学报 (医学版), 2025, 63(2): 29-35.
[4]	山东省腔镜外科质量控制中心胸腔镜委员会. 山东省VATS/RATS非小细胞肺癌围术期质量控制指标专家共识(2025版)[J]. 山东大学学报 (医学版), 2025, 63(12): 1-5.
[5]	刘振昆,吕纪玲,徐伟伟,马力天,张才擎. BALF tNGS检测及培养对NSCLC合并IPFD的诊断价值[J]. 山东大学学报 (医学版), 2025, 63(11): 36-45.
[6]	张荣雨,赵文,李洪欣,杨闯,王健,韩春燕,李际盛. 奥西替尼联合化疗一线治疗EGFR-RAD51融合突变转移性肺腺癌1例[J]. 山东大学学报 (医学版), 2024, 62(5): 116-120.
[7]	冯绪梅,宋相庆,季冠虹,赵小刚,肖兆华. 血浆外泌体miR-548k在食管鳞癌中的表达及诊断价值[J]. 山东大学学报 (医学版), 2024, 62(5): 79-88.
[8]	梁永媛,蔡培飞,郑桂喜. 基于多检验变量和机器学习算法的结肠癌诊断模型建立及价值评估[J]. 山东大学学报 (医学版), 2024, 62(2): 51-59.
[9]	董雅琪,王新慧,赵颖慧,王传新. 血清外泌体LINC02163作为结直肠癌远处转移标志物的临床价值[J]. 山东大学学报 (医学版), 2023, 61(9): 19-28.
[10]	赵元元,路军涛,吴小华. 人脐带间充质干细胞外泌体miR-100对多囊卵巢综合征患者颗粒细胞炎症的影响[J]. 山东大学学报 (医学版), 2023, 61(5): 51-58.
[11]	秦静,杨飞,陈谦,夏涵岱,刘延国,王秀问. 晚期驱动基因阴性、PD-L1表达阴性非鳞非小细胞肺癌一线治疗方案的网状Meta分析[J]. 山东大学学报 (医学版), 2022, 60(7): 74-82.
[12]	陈兆波,方敏,薛浩然,刘春艳. 去泛素化酶USP35促进非小细胞肺癌细胞迁移和侵袭[J]. 山东大学学报 (医学版), 2022, 60(4): 30-37.
[13]	马瑞杰,朱良明,左太阳,李春海,张楠,孙志钢. 微波消融治疗非小细胞肺癌根治术后肺寡转移瘤的预后分析[J]. 山东大学学报 (医学版), 2022, 60(12): 63-68.
[14]	刘会宁,彭军,任迎春,杨光,王文豪,刘金锋,田勍. 34例胸腔镜下肺楔形切除与21例肺段切除对位于肺段P区的ⅠA1期非小细胞肺癌治疗比较[J]. 山东大学学报 (医学版), 2022, 60(11): 38-43.
[15]	李雁儒,李娟,李培龙,杜鲁涛,王传新. 胰腺癌不同进展期血清外泌体蛋白质组学分析[J]. 山东大学学报 (医学版), 2022, 60(10): 33-41.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed